
Please try another search
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. It develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. The company is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinical trial; and TMB-365 and TMB-380 combination, a monoclonal antibody combination therapy for HIV that is in phase-1b/2a clinical trial, as well as antibody-drug conjugates, for cancer treatment. In addition, it offers contract development and manufacturing services. The company has a research and development agreement for Trogarzo TMB-355 with Genentech and Biogen Inc., and authorizes Samsung Biologics to produce TMB-355. TaiMed Biologics Inc. was incorporated in 2007 and is headquartered in Taipei City, Taiwan.
Name | Age | Since | Title |
---|---|---|---|
Ta-mon Tseng | 67 | 2018 | Director |
Chin-Ming Chang | - | 2018 | President, CEO & Director |
Gwo-Fong Lin | 70 | 2020 | Independent Director |
Chi-Chuan Chen | 67 | 2013 | Director |
Chin-Ting Chiu | - | 2022 | Independent Director |
Shiren S. Lee | 64 | 2017 | Independent Director |
Ming-Tsuen Chen | - | 2025 | Chairman of the Board |
Shih Chia Lin | - | 2022 | Director |
C. C. Cheng | - | 2025 | Director |
Lin Shih Chia | - | 2025 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review